Humanized Major Histocompatibility Complex Transgenic Mouse Model Can Play a Potent Role in SARS-CoV-2 Human Leukocyte Antigen-Restricted T Cell Epitope Screening
Open Access
Abstract
Background: COVID-19, caused by SARS-CoV-2, poses a significant threat to human health. Vaccines designed for T-cell epitopes play an important role in eliminating the virus. However, T cell epitope screening often requires the use of a large number of peripheral blood mononuclear cells (PBMCs) from infected or convalescent patients, and if MHC humanized mice can be used for epitope screening, they will not have to wait for enough PBMCs to be available to screen for epitopes, thus buying time for epitope confirmation and vaccine design. Methods: In this study, we used SARS-CoV-2 BA.5 to infect HLA-A11/DR1, C57BL/6, hACE2 mice, and detected body weight changes, viral load, and pathological changes after infection. Fourteen days after the HLA-A11/DR1 and C57BL/6 mice were immunized against inactivated viruses, IgG antibodies were detected in mouse serum using ELISA, and IFN-γ produced by peptide stimulation of splenocytes was detected by ELISpot. Results: There is no obvious pathogenic phenotype of SARS-CoV-2 infection in HLA-A11/DR1 mice. Specific IgG antibodies were detected in serum after immunization of inactivated virus in both HLA-A11/DR1 and C57BL/6 mice, but specific IFN-γ was detected in splenocytes of HLA-A11/DR1 mice. Conclusions: Although HLA-A11/DR1 mice are unable to replicate the virus effectively in vivo, they are able to generate cellular immune responses after immunization inactivated viruses. Therefore, it can be used as a tool to substitute for human PBMCs in epitope screening, thus shortening the timeliness of T cell epitope screening and obtaining the immunogenicity information of new epitopes in a timely manner.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFC2303502, SKLPBS2224, 82341046)
- State Key Laboratory of Pathogen and Biosecurity (2022YFC2303502, SKLPBS2224, 82341046)
- National Natural Science Foundation of China (2022YFC2303502, SKLPBS2224, 82341046)
This publication has 52 references indexed in Scilit:
- SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiencyCell, 2024
- Parallel detection of SARS‐CoV‐2 epitopes reveals dynamic immunodominance profiles of CD8+ T memory cells in convalescent COVID‐19 donorsClinical & Translational Immunology, 2022
- High‐resolution analysis of individual spike peptide‐specific CD4+ T‐cell responses in vaccine recipients and COVID‐19 patientsClinical & Translational Immunology, 2022
- Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variantsCell Reports, 2021
- The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2Biochimie, 2020
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease SeverityCell, 2020
- A Mouse Model of SARS-CoV-2 Infection and PathogenesisCell Host & Microbe, 2020
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike GlycoproteinCell, 2020
- The current state of animal models in research: A reviewInternational Journal of Surgery, 2019
- A mouse model of human adaptive immune functions: HLA‐A2.1‐/HLA‐DR1‐transgenic H‐2 class I‐/class II‐knockout miceEuropean Journal of Immunology, 2004